Psilocybin and Cardiovascular Safety
Explore mushroom research and guides on psilocybin and cardiovascular safety.
5-HT2B and Cardiac Valvulopathy: Psilocybin Safety
Psilocin activates the 5-HT2B receptor linked to heart valve damage from fenfluramine. What receptor affinity data and clinical evidence say about risk.
Psilocybin Cardiovascular Risk Assessment
Before psilocybin therapy, clinicians screen cardiac risk across three domains. Here's what ECG, blood pressure, and cardiac history checks actually assess.
Psilocybin and Heart Safety: Blood Pressure and Heart Rate Effects
A meta-analysis found psilocybin raises blood pressure by ~19 mmHg systolic on average, while pooled heart rate stayed comparable to placebo and acute effects resolved within 48 hours. What the data shows.
Psilocybin and QTc: What Cardiac Monitoring Data Shows
At 25mg psilocybin the average QTc change is 2.1ms, far below the 10ms safety threshold. Here's what cardiac monitoring data from clinical trials shows.